Lantern Pharma Finalizes $4.4M Offering with Warrants, Addresses Going Concern

summarizeSummary

Lantern Pharma finalized a $4.4 million offering of common stock and pre-funded warrants, along with concurrent private placement warrants, to secure critical funding and extend its operating runway until Q1 2027, addressing a 'going concern' warning.

check_boxKey Events

• Finalized Public Offering

  The company is offering 1,454,175 shares of common stock at $2.06 per share and 681,748 pre-funded warrants (exercisable at $0.0001) at a purchase price of $2.0599 each, totaling approximately $4.4 million in gross proceeds.

• Concurrent Private Placement Warrants

  In a concurrent private placement, the company is also issuing warrants to purchase up to 2,135,923 shares of common stock at an exercise price of $2.27 per share. Additionally, placement agent warrants for 106,796 shares at $2.575 are being issued.

• Significant Dilution and Capital Raise

  The offering is expected to generate approximately $3.94 million in net proceeds for working capital. If all warrants are exercised for cash, the total potential capital raise could exceed $9.5 million, leading to a potential dilution of approximately 38.7% of outstanding shares.

• Addresses Going Concern Warning

  The proceeds are crucial for the company, which previously disclosed a 'going concern' warning. This financing is projected to fund operations until the middle of the first calendar quarter of 2027.

auto_awesomeAnalysis

Lantern Pharma has finalized a significant capital raise, securing approximately $3.94 million in net proceeds from an offering of common stock and pre-funded warrants. This financing is critical as the company previously disclosed a 'going concern' warning, and these funds are expected to extend its operating runway until the first quarter of 2027. The offering is highly dilutive, with the potential to issue over 4.3 million new shares (including all warrants) against 11.3 million outstanding shares, representing a substantial increase in share count. The offering price of $2.06 per share is at a discount to recent market prices, reflecting the company's urgent need for capital.